TL;DR (Summary) ~15% reduction in visceral fat Minimal change in subcutaneous fat No major safety signal in randomized controlled trials This is one of the few interventions shown to selectively reduce visceral fat in humans
Freeze only the dry vial if long-term storage is needed
[DOI] [PubMed] [Google Scholar] 104.Egecioglu E, Ploj K, Xu X, et al
There are no FDA-approved dosing guidelines for GHK-Cu because it is not an FDA-approved drug for any indication
What patients really need is evidence-based care that allows clinicians to adjust dosing over time so were using the right dose for the right patient at the right time. GLP-1 medications can be a game-changer, but they work best when used as part of a broader strategy that includes nutrition, physical activity and long-term support
This echoes a broader challenge in the supplement industry, where individual responses vary dramatically based on baseline nutritional status, diet quality, medication dosage, and other factors
